State of Tennessee Treasury Department Sells 779 Shares of IDEXX Laboratories, Inc. (IDXX)

State of Tennessee Treasury Department lessened its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.2% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 33,848 shares of the company’s stock after selling 779 shares during the quarter. State of Tennessee Treasury Department’s holdings in IDEXX Laboratories were worth $5,263,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. WMS Partners LLC boosted its position in shares of IDEXX Laboratories by 0.3% in the second quarter. WMS Partners LLC now owns 1,583 shares of the company’s stock valued at $256,000 after acquiring an additional 4 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its stake in IDEXX Laboratories by 0.3% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 6,547 shares of the company’s stock valued at $1,057,000 after purchasing an additional 19 shares in the last quarter. CAPROCK Group Inc. raised its stake in IDEXX Laboratories by 2.2% in the second quarter. CAPROCK Group Inc. now owns 1,830 shares of the company’s stock valued at $295,000 after purchasing an additional 40 shares in the last quarter. Strs Ohio raised its stake in IDEXX Laboratories by 0.7% in the second quarter. Strs Ohio now owns 5,929 shares of the company’s stock valued at $957,000 after purchasing an additional 41 shares in the last quarter. Finally, National Asset Management Inc. raised its stake in IDEXX Laboratories by 2.1% in the second quarter. National Asset Management Inc. now owns 2,051 shares of the company’s stock valued at $332,000 after purchasing an additional 42 shares in the last quarter. 88.03% of the stock is owned by institutional investors.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) opened at $149.54 on Wednesday. The company has a debt-to-equity ratio of -12.48, a quick ratio of 0.77 and a current ratio of 0.95. The company has a market capitalization of $12,890.05, a PE ratio of 49.76, a price-to-earnings-growth ratio of 2.23 and a beta of 0.46. IDEXX Laboratories, Inc. has a 52 week low of $109.35 and a 52 week high of $173.01.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, October 31st. The company reported $0.79 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.74 by $0.05. IDEXX Laboratories had a negative return on equity of 336.64% and a net margin of 14.55%. The firm had revenue of $492.00 million during the quarter, compared to the consensus estimate of $492.94 million. During the same quarter in the previous year, the firm earned $0.62 earnings per share. The business’s quarterly revenue was up 9.7% on a year-over-year basis. sell-side analysts forecast that IDEXX Laboratories, Inc. will post 3.24 EPS for the current year.

A number of research analysts recently commented on the company. BidaskClub downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Zacks Investment Research raised IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $186.00 price target for the company in a research note on Wednesday, July 19th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $185.00 price target on shares of IDEXX Laboratories in a research note on Tuesday, October 24th. CL King raised IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 price target for the company in a research note on Friday, July 28th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $180.00 price target on shares of IDEXX Laboratories in a research note on Friday, October 6th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. IDEXX Laboratories presently has an average rating of “Hold” and an average target price of $173.67.

In other news, Director Rebecca M. Henderson sold 2,578 shares of the company’s stock in a transaction that occurred on Tuesday, August 22nd. The stock was sold at an average price of $152.86, for a total value of $394,073.08. Following the completion of the transaction, the director now owns 17,274 shares of the company’s stock, valued at $2,640,503.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman Jonathan W. Ayers sold 13,000 shares of the company’s stock in a transaction that occurred on Monday, August 28th. The shares were sold at an average price of $150.79, for a total value of $1,960,270.00. Following the completion of the transaction, the chairman now directly owns 1,044,034 shares of the company’s stock, valued at approximately $157,429,886.86. The disclosure for this sale can be found here. Insiders sold 92,734 shares of company stock valued at $14,083,486 in the last ninety days. 2.77% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION NOTICE: This article was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://ledgergazette.com/2017/11/15/state-of-tennessee-treasury-department-sells-779-shares-of-idexx-laboratories-inc-idxx.html.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply